checkAd

     357  0 Kommentare Vir Biotechnology Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD’s The Liver Meeting 2023

    SAN FRANCISCO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that eight abstracts highlighting new data from its chronic hepatitis B (CHB) and chronic hepatitis delta (CHD) clinical programs have been accepted for presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting, taking place in Boston, MA, from November 10-14, 2023. These include seven poster presentations, one of which is a late-breaking poster, and one late-breaking oral presentation.

    “Results from our ongoing studies underscore the tremendous progress we are making toward addressing the needs of the millions of people living with chronic hepatitis B and chronic hepatitis delta,” said Phil Pang, M.D., Ph.D., Vir’s Executive Vice President, Chief Medical Officer and Interim Head of Research. “We are eager to present additional data from our multiple ongoing trials at AASLD, especially the data from two late-breaking presentations on the potential clinical impact that VIR-3434 and VIR-2218 could have for both CHB and CHD patients.”

    Presentations
         
      Title: VIR-2218 and VIR-3434 therapy is efficacious in preclinical models of hepatitis delta virus infection (Poster #1257-C)
        Session: Poster Session 1
        Date: Friday, November 10
        Time: 12:00 p.m. ET
        Presenter: Jiayi Zhou, MBA, Senior Research Associate, Virology at Vir Biotechnology
         
      Title: Pharmacokinetics and safety of VIR-2218 monotherapy in adult cirrhotic participants with moderate hepatic impairment (Poster #1480-C)
        Session: Poster Session 1
        Date: Friday, November 10
        Time: 12:00 p.m. ET
        Presenter: Sneha V. Gupta, Ph.D., Director, Clinical Pharmacology at Vir Biotechnology
         
      Title: Initial evaluation of immune complex binding in a phase 1 safety and tolerability study of chronic HBV participants given a single dose of VIR-3434 (Poster #1511-C)
        Session: Poster Session 1
        Date: Friday, November 10
        Time: 12:00 p.m. ET
        Presenter: Rachel Wong, Ph.D., Clinical Immunology Scientist at Vir Biotechnology
         
      Title: Assessment of regional impact on the pharmacokinetics of VIR-2218 (BRII-835) in subjects with chronic hepatitis B virus infection (Poster #1457-C)
        Session: Poster Session 1
        Date: Friday, November 10
        Time: 12:00 p.m. ET
        Presenter: Yali Zhu, Senior Director, Clinical Pharmacology at Brii Biosciences & Sneha V. Gupta, Ph.D., Director, Clinical Pharmacology at Vir Biotechnology
         
      Title: Prevalence of hepatitis B and D virus among a nationally representative insured population in the United States (Poster #1379-C)
        Session: Poster Session 1
        Date: Friday, November 10
        Time: 12:00 p.m. ET
        Presenter: Sacha Satram, Ph.D., Director, Health Economics & Outcomes Research at Vir Biotechnology
         
      Title: Predictors of treatment initiation among high-risk and grey area chronic hepatitis B patients in a real-world clinical practice setting in the United States (Poster #1326-C)
        Session: Poster Session 1
        Date: Friday, November 10
        Time: 12:00 p.m. ET
        Presenter: Sacha Satram, Ph.D., Director, Health Economics & Outcomes Research at Vir Biotechnology
         

    Additional details on the late breaking poster and oral presentations will be shared on November 10, 2023.

    Seite 1 von 4



    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Vir Biotechnology Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD’s The Liver Meeting 2023 SAN FRANCISCO, Oct. 11, 2023 (GLOBE NEWSWIRE) - Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that eight abstracts highlighting new data from its chronic hepatitis B (CHB) and chronic hepatitis delta (CHD) clinical programs have been …